C Worldwide Thematic Specialist Morten Springborg believes stock-market analysts are likely to miss out on important investment themes — including the growth potential for makers of innovative weight-loss medications — because they don’t look out far enough.
C Worldwide is based in Copenhagen and manages about $18 billion, mainly in international strategies. It manages the Harbor International Compounders ETF OSEA, taking an active concentrated approach with 28 holdings. Top holdings of OSEA Here are the largest 10 holdings of the Harbor International Compounders ETF. We have included two-year expected compound annual growth rates for sales and earnings per share for the companies, based on consensus estimates among analysts working for brokerage firms polled by FactSet. Also included are projected weighted CAGR for companies held by the iShares MSCI ACWI ex U.S. ETF ACWX, which tracks the MSCI AC ex U.S.A.
Novo Nordisk Springborg said investors and analysts were underestimating the potential for the use of Novo Nordisk’s Wegovy and Eli Lilly & Co.’s LLY, +1.22% competing Ozempic medication. The drugs are being used currently to treat obesity and Type 2 diabetes. This fits into one of C Worldwide’s long-term themes — “lifestyle diseases.” Springborg said he expected the medications to be used to treat kidney disease as well.